Over the last decade, adjuvant chemotherapy has undergone a significant improvement, Philip says. The field has seen evolution from single-agent gemcitabine to gemcitabine plus capecitabine to FOLFRINOX. Most recently, the PRODIGE 24/CCTG PA.6 trial study demonstrated a significant improvement in survival for patients with resectable pancreatic cancer treated with modified FOLFIRINOX (mFOLFIRINOX) versus gemcitabine. Read more . . .